18 |
Neuroscience |
CVB2023 |
Grabody B, an IGF1 receptor based shuttle, mediates efficient delivery of biologics across the blood brain barrier |
|
17 |
ABL001 |
PEGS 2017 |
Preclinical development of an anti-cancer bispecific antibody targeting VEGF and DLL4, ABL001 |
|
16 |
ABL001 |
ASCO 2019 |
Phase 1a study results investigating the safety and preliminary efficacy of ABL001 (NOV1501), a bispecific antibody targeting VEGF and DLL4 in metastatic gastrointesinal (GI) cancer |
|
15 |
ABL001 |
PEPTALK 2020 |
Summary of phase 1a dose escalation clinical study data for dual angiogenic bispecific antibody targeting VEGF and DLL4 (ABL001/NOV1501/TR009) in patients with previously treated solid tumors |
|
14 |
ABL105 |
ESMO2021 |
A novel HER2/4-1BB bispecific antibody, YH32367 (ABL105) exerts significant anti-tumor effects through tumor-directed T cell activation |
|
13 |
4-1BB Platform |
AACR 2020 |
B7-H3-targeted 4-1BB activation potentiates CD8 T cell-dependent antitumor immunity without systemic toxicity |
|
12 |
4-1BB Platform |
AACR 2021 |
A novel anti-CD137 antibody recognizing the membrane-proximal CD137 domain elicits potent anti-tumor T cell activity in a bispecific antibody format |
|
11 |
ABL503 |
SITC2021 |
ABL503 (TJ-L14B), PD-L1×4-1BB bispecific antibody, induces superior anti-tumor activity by PD-L1-dependent 4-1BB activation with the increase of 4-1BB+CD8 + T cells in tumor microenvironment |
|
10 |
ABL503 |
PEGS 2019 |
The PD-L1 x 4-1BB Bispecific Antibody ABL503 Shows Potent Anti-Tumor Effect through Tumor-Directed T Cell Activation |
|
9 |
ABL111 |
SITC2021 |
TJ-CD4B (ABL111), a Claudin18.2-targeted 4-1BB tumor engager induces potent tumordependent immune response without dose-limiting toxicity in preclinical studies |
|